University of California, Davis

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of California, Davis sits in the top decile of US sponsors by registered trial count (#52 of 15,742 sponsors by registered trial count).

657 total trials 123 currently recruiting 435 completed early-phase tilt top decile by trial count

University of California, Davis: 657 sponsored US clinical trials, 123 recruiting.

University of California, Davis sponsors 657 registered US clinical trials on ClinicalTrials.gov, 123 of them currently recruiting, and 435 completed. 38 of these trials are in Phase 3-4 (later-stage) and 129 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 12 trials.

Top-decile sponsor footprint

University of California, Davis ranks in the top decile of sponsors by registered trial count (#52 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 65/100

435 of 483 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

657 total, page 14 of 14

COMPLETED Phase 1

Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors

NCT00389584
COMPLETED Phase 2

Monocyte Function and Inflammation in Type 1 Diabetes and Its Modulation

NCT00441844
COMPLETED Phase 1

Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

NCT00390429
COMPLETED NA

Simultaneous Care: Linking Palliation to Clinical Trials

NCT00283257
COMPLETED NA

Radiofrequency Ablation in Treating Patients With Early Invasive Breast Cancer or Ductal Carcinoma in Situ

NCT00388115
COMPLETED Phase 2

Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer

NCT00387660
COMPLETED Phase 2

Balloon Prophylaxis of Aneurysmal Vasospasm

NCT00282893
← Previous Page 14 of 14

Phase Distribution

PhaseTrial count
Phase 1 86
Phase 2 43
Phase 3 10
Phase 4 28

Therapeutic Areas

Healthy 12
Obesity 8
Inflammation 5
Metabolic Syndrome 5
Autism Spectrum Disorder 5
Scarring 4
Breast Cancer 4
Lung Cancer 4
Psoriasis 4
Head and Neck Cancer 4

What is open in the University of California, Davis pipeline

123 recruiting of 657 indexed (19% open); 435 completed (66%).

Phase mix: 38 late (III/IV) vs 129 early (I/II) (early-phase heavy).

Top condition: Healthy (12 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of California, Davis: open-pipeline peers nationwide

Peers matched on 657 registered trials and 19% open enrollment, not the therapeutic-area sidebar.

University of California, Davis sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600800 0%5%10%15%20%25% Total trials Recruiting share University of California, DavisVanderbilt University Medical CenterUniversity of RochesterUS Department of Veterans AffairsThe Cleveland ClinicEyePoint PharmaceuticalsHebrew SeniorLifeInsulet CorporationMedical University of South Carolina
University of California, Davis sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of California, Davis sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 657 trials (± recruiting share)

Sponsors near 19% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this University of California, Davis page

657 registered trials is a research-attention snapshot, not an endorsement of University of California, Davis or any single study.

  • 123 of University of California, Davis's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Healthy is the condition University of California, Davis studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, Davis pipeline card: 657 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.